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ABSTRACT 27 
When grown in a semi-defined medium, L. fermentum Lf2 synthesizes significant 28 
quantities (~2 g/L) of two exopolysaccharides (EPS). The two EPS were separated by 29 
preparative size exclusion chromatography to give a high molecular mass -glucan 30 
(1.23 x 106 Da) and a medium molecular mass heteroglycan (8.8 x 104 Da). The 31 
structure of the high molecular mass -glucan was determined using a combination of 32 
NMR spectroscopy, monomer and linkage analysis.  The EPS has the following 33 
structure: 34 
                        →3)--D-Glcp-(1→3)--D-Glcp-(1→ 35 
2 36 
 37 
1 38 
-D-Glcp 39 
 40 
The immunomodulatory activity of the high molecular mass EPS was studied in 41 
peripheral blood mononuclear cells (PBMC). Exposure of PBMC to an aqueous 42 
solution of the EPS for 24 h led to increased cell proliferation, changes in expression 43 
of the cytokines CD14 and TLR2, and to an increase in production of TNF-compared 44 
to controls. In contrast, when cells that had been treated with EPS for 24 h and from 45 
which the EPS had been removed, were subsequently exposed to the bacterial 46 
antigen LPS very low levels of TNF- production were observed. This result indicates 47 
that the EPS imparts immunotolerance in PBMC.  An ability to modulate the release of 48 
the proinflammatory mediators, such as TNF-, is an important goal in the 49 
development of therapies for the treatment of diseases, such as Crohn’s disease and 50 
ulcerative colitis, associated with excessive release of inflammatory mediators.  51 
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1. Introduction 52 
In the last ten years, significant advances have been made in determining the role that 53 
the microflora resident in the human gastrointestinal tract (GIT) play in maintaining the 54 
health of their hosts [1-4]. A growing number of diseases, including obesity [5, 6], liver 55 
disease [7, 8], cancer [9, 10], inflammatory bowel dieases [11-13] and 56 
neurodegenerative diseases [14-16], have been linked to changes in the populations 57 
of bacteria in the gut.  The molecular mechanisms through which the gut microbiota 58 
interact with their mammalian hosts is the topic of current research and much of this 59 
work focuses on activities occurring at the gastrointestinal (GI) barrier [17, 18]. The GI 60 
barrier separates the intestinal gut microflora from the systemic blood and organs of 61 
the body and is composed of a layer of epithelial cells coated in mucin.  In a correctly 62 
functioning barrier, the presence of highly viscous mucin and a tightly packed layer of 63 
epithelial cells prevents the bacteria passing through to the underlying organs. The 64 
barrier is not a passive organ and active communication occurs between the 65 
commensal bacteria and the professional immune cells that live just below the barrier 66 
[17]. Whilst a number of different methods of communication exist, one of the best 67 
understood is the signalling initiated by the lipopolysaccharide (LPS) of Gram-negative 68 
bacteria [19].  LPS binds to the pattern recognition receptors, TLR 2 and 4 [20], which 69 
are present on the surface of epithelial cells. Binding of LPS by TLR4 occurs in 70 
combination with CD14 and gives rise to a signalling cascade that releases 71 
proinflammatory mediators, including TNF-into the lamina propria below the barrier 72 
[19]. The release of TNF- ultimately leads to a range of pro-inflammatory responses 73 
[21] which provide protection against pathogenic bacteria but can also initiate 74 
overactive inflammation which is central to the aetiology of a range of pathologies 75 
such as inflammatory bowel disease. 76 
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It has been reported that exopolysaccharides (EPS) [22, 23 ] [24, 25] secreted by 77 
Gram-positive bacteria, can influence the release of both pro- and anti-inflammatory 78 
mediators. It has also been shown that specific EPS can modulate the immune 79 
response generated by other bacterial antigens and, in doing so, provide a degree of 80 
immunotolerance [24]. It is likely that immunotolerance has evolved as a way of 81 
preventing damage that can occur through too robust an immune response e.g. as 82 
occurs in autoimmune diseases [26]. One of the potential molecular mechanisms for 83 
inducing immunotolerance is through the interaction of bacterial antigens, including 84 
exopolysaccharides, with pattern recognition receptors present on the host cell surface 85 
[27-29].  Unfortunately, progress in understanding the molecular mechanisms by 86 
which EPS can induce immunotolerance has been restricted by the limited availability 87 
of high purity EPS that can be used in cell culture studies and it is this area of work the 88 
current paper addresses. 89 
L. fermentum Lf2  is a lactic acid bacteria (LAB) that was isolated as a contaminant 90 
culture during cheese manufacture [30]. Under optimized conditions, the strain 91 
produces significant quantities of a mixture of EPS (~2g/L).  It has previously been 92 
demonstrated that the EPS mixture has immunomodulatory activity [31]. The aim of 93 
the current study was purity the polysaccharides, to characterize the high molecular 94 
mass EPS and to investigate its immunomodulatory activity with peripheral blood 95 
mononuclear cells (PBMC). These cells are easily isolated from whole blood and 96 
although there are some small differences in the composition and activation status 97 
compared with the immune cells of the gastrointestinal tract, they share certain key 98 
phenotypic characteristics [32] and have previously been used to study the behaviour 99 
of mucosal immunity of the GI-tract [33].  100 
2. Results and Discussion 101 
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2.1 Composition of the crude EPS and isolation of a high molecular mass EPS. 102 
SEC-MALLS analysis of the crude EPS produced by L. fermentum Lf2 identified that a 103 
mixture of macromolecules was being secreted into the surrounding medium during 104 
fermentation, including a high molecular mass EPS (HMw-EPS), a medium molecular 105 
mass EPS and a UV absorbing species with a low molecular mass (data not shown). 106 
After preparative size exclusion chromatography a pure sample of the HMw-EPS was 107 
obtained in the early eluting fractions. The SEC-MALLS trace for the purified HMW-108 
EPS contained a single peak (RT= 26 mins) with a weight average molecular mass of 109 
1.23 x 106 Da and a polydispersity value of 1.104. The molecular mass and 110 
polydispersity are similar to those recorded for EPS isolated from other LAB [34]. The 111 
next fractions that eluted from the SEC included a combination of the medium 112 
molecular mass polysaccharide and the UV absorbing species, believed to be small 113 
amounts of cell wall material, that could not be separated. 114 
2.2 Characterization of the HMw-EPS.  115 
Monomer analysis and determination of the absolute configuration of the 116 
monosaccharides identified that the HMw-EPS was composed entirely of D-glucose 117 
confirming that the material was a glucan. Linkage analysis, using permethylated 118 
alditol acetates, confirmed the presence of a 1,5-di-O-acetyl-2,3,4,6-tetra-O-119 
methylglucitol (corresponding to a terminal glucopyranose), a 1,3,5-tri-O-acetyl-2,4,6-120 
tri-O-methylglucitol (corresponding to a 1,3-linked glucopyranose) and a 1,2,3,5-tetra-121 
O-acetyl-4,6-di-O-methylglucitol (corresponding to a 1,2,3-linked glucopyranose) in an 122 
approximately 1:1:1 ratio.  123 
The 1H-NMR spectrum (Fig 1, top, F2-axis) had two distinct resonances in the 124 
anomeric region (4.893 & 4.821 ppm) with an integral ratio of 1:1.9 which is consistent 125 
with the EPS having a trisaccharide repeating unit. Each of the anomeric signals had 126 
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large 3JH1,H2-coupling constants (7.7 & 7.4 Hz) which is indicative of -linked hexoses 127 
[35]. 128 
 129 
Fig 1. (A) Top (F2-axis) selected regions of the 1H NMR spectrum for the HMw-EPS 130 
recorded at 70 oC on a Bruker 600 MHz spectrometer; (B) Blue Contours: 1H-1H 131 
COSY spectrum for the HMw-EPS recorded at 70 oC; (B) Black contours: 1H-1H-132 
TOCSY spectrum recorded at 70 oC. Labels (A-C) identify the different 133 
monosaccharides and the numbers (1-6) identify the respective ring protons. 134 
 135 
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The location of the H2 protons was identified through inspection of a 1H-1H-COSY 136 
spectrum (Fig 1, blue contours) and identification of the H1-H2 cross peaks.  137 
Fortunately, each H2 appears in a clear part of the spectrum and each has a unique 138 
chemical shift; these were labelled A2 (3.273 ppm), B2 (3.813 ppm) and C2 (3.585 139 
ppm). The positions of the remaining ring protons were determined by following the 140 
transmission of scalar coupling (H2 through to H6) on the 1H-1H-TOCSY spectrum (Fig 141 
1, black contours). A combination of an edited 1H-13C-HSQC spectrum (not shown) 142 
and a  1H-13C-HSQC-TOCSY spectrum (Fig 2) was used to identify the location of the 143 
carbon resonances. 144 
 145 
Fig. 2. 13C-1H HSQC-TOCSY spectrum for the HMw-EPS recorded in solution in D2O 146 
(5-10 mg in 0.65 mL) at 70 oC on a Bruker 400MHz spectrometer, labels (A-C) identify 147 
the different monosaccharides and the numbers (1-6) identify the respective ring 148 
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carbons; resonances highlighted in circles correspond to the three HSQC cross peaks 149 
used to establish correlations. 150 
The chemical shifts for the individual proton and carbons are listed in Table 1. 151 
The chemical shifts for the protons and carbons of residue A are consistent with A 152 
being a terminal -linked glucopyranose monomer [36]. The low field shift of both the 153 
C2 and C3 signals in residue B are consistent with B being a 1,2,3-linked 154 
glucopyranose  Similarly, the low field shift of  C C3 identifies C as a 1,3-linked 155 
glucopyranose. The latter combination of linkages is consistent with the structure of 156 
the repeat unit of the HMw-EPS being: 157 
   C          B 158 
→3)--D-Glcp-(1→3)--D-Glcp-(1→ 159 
                               2 160 
                                161 
                               1 162 
-D-Glcp 163 
         164 
                                 A 165 
The linkage residue A to the 2-position of B was confirmed by examination of a 166 
ROESY spectrum (data not shown) on which an inter-residue NOEs was observed 167 
between A H1 and B H2.   168 
 169 
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Table 1.Proton and carbon chemical shifts (ppm) for the Lf2 HMW-EPS recorded in 170 
D2O at 70 oC. Chemical shifts are referenced to external acetone 2.225 ppm for 1H 171 
and 31.55 ppm for 13C. Labels (A-C) identify the different monosaccharides and the 172 
numbers (1-6) identify the respective carbons/ protons. 173 
 174 
A number of microorganisms, including fungi and bacteria, generate -glucans 175 
that have main chains composed of -(1,3)-linked glucoses [37, 38] but  only a small 176 
number include 1,2-linked branches. Three bacterial species generate EPS that are 177 
identical to that reported here and these are Oenococcus oeni I4 [39], Pediococcus 178 
damnosus 2.6 [40] and one of the two EPSs produced by Lactobacillus spp. G-77 [40, 179 
41].  Whilst Streptococcus pneumoniae Type 37 produces a CPS having a main chain 180 
of -(1,3)-glucoses where each glucose in the main chain has a terminal 181 
glucose,connected via a -link, at C2 [42].  182 
2.3 PBMC activation and cell culture.  183 
It has previously been reported that the crude EPS extract from L. fermentum Lf2 has 184 
biological activity: the EPS mixture protected mice against Salmonella infection and  185 
moderate immunomodulatory activity was demonstrated [31]. In order to determine if 186 
the biological activity was associated with the HMW-EPS, a range of experiments were 187 
undertaken to study the response of the exposure of peripheral blood mononuclear 188 
cells (PBMC) tothe HMW-EPS in the absence or presence of the stimulants 189 
lipopolysaccharide (LPS) and phytohaemagglutinin (PHA). 190 
In the first experiments, PBMC isolated from different donors were exposed to 191 
two concentrations of the purified HMw-EPS. In all donors, the metabolic activity of the 192 
cells increased after treatment with the HMw-EPS (p < 0.001 - 0.0001) (Fig 3A).  193 
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 194 
Fig. 3.  Non-radioactive MTS assay was used for measuring metabolic activity of the 195 
cells under different culture conditions as measured after A. Experiment 1, Day 1 and 196 
B. Experiment 2, Day 2. A For Experiment 1, Unstimulated conditions were left 197 
untreated while Lf2 HMw 50µg/ml and Lf2 HMw 100µg/ml were treated with EPS at 198 
indicated concentrations on Day 0 and incubated at 37˚C, 5% CO2.  Following 24h 199 
incubation, cells were harvested and 1x105 cells/well were transferred into 96-well 200 
plates for MTS assay performed following the supplier’s instructions.  B For 201 
Experiment 2, Day 2, Unstimulated condition was left untreated on Day 0 then washed 202 
and left unstimulated on Day 1.  Lf2 HMw 100µg/ml were pre-treated at Day 0 with 203 
indicated concentration of EPS, then washed and left unstimulated on Day 1.  LPS 204 
and PHA alone are conditions that were left untreated on Day 0, then washed and 205 
subsequently stimulated with 100ng/ml LPS and 10µg/ml PHA, respectively.  EPS + 206 
LPS and EPS + PHA represent the conditions that were pre-treated with EPS Lf2 207 
HMw on Day 0, washed and stimulated with 100ng/ml LPS and 10µg/ml PHA, 208 
respectively on Day 1.  Following 24h incubation, cells were harvested and 1x105 209 
cells/well were transferred into 96-well plates for MTS assay performed following the 210 
supplier’s instructions.  Two-Way ANOVA was used to compare the conditions for 211 
each donor.  Data are presented as Mean ± SEM.  * p < 0.05, ** p < 0.01, *** p < 212 
0.001, **** p < 0.0001 when compared to the untreated, unstimulated condition; # p < 213 
0.05, ### p < 0.001, #### p < 0.0001 when compared between two indicated 214 
conditions. 215 
 216 
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The levels of activation were comparable for both EPS concentrations used (50 217 
µg/mL and 100 µg/mL), except for Donor B where higher levels were obtained for 50 218 
µg/mL EPS (p < 0.0001). The results suggest that the EPS did not have a negative 219 
impact on the viability of the cells.  At the concentrations employed, the EPS was able 220 
to activate PBMC in culture compared to controls, indicating a functional interaction 221 
between the two.  Interestingly, this activation persisted for 24 h after the EPS had 222 
been removed from solution (see discussion below). This is in agreement with 223 
previous reports where cell wall extracts and purified EPS stimulated cell proliferation 224 
of different immune cell types: including BALB/c mice splenocytes and mesenteric 225 
lymphocytes [43] using EPS from LAB, and mouse lymphocytes by EPS from 226 
Paenibacillus jamilae CP-7 [44]. In contrast, EPS from bifidobacteria has been 227 
reported to have anti-proliferative activity on rat PBMC and gut associated lymphoid 228 
tissue cells [45]. Whilst other authors have reported bifidobacteria EPS stimulates 229 
proliferation of the intestinal cell line Caco-2 but not HT-29 [46] the EPS from 230 
Lactobacillus gasseri strains G10 and H15 had no effect on the proliferation of the 231 
cervical cancer cell line HeLa [47].  These differences are not surprising since it has 232 
previously been demonstrated that EPS can exert a differential effect on the metabolic 233 
activity of different cell types [48].   234 
In the next set of experiments, PBMC were initially exposed to the HMW-EPS for 235 
24 h after which time the EPS was removed. The cells were then incubated for a 236 
further 24 h either without any additional treatment or by exposing the cells to one of 237 
the stimulants LPS or PHA. Appropriate duplicate controls, in which cells were not 238 
treated with EPS, were run for each of the experiments. In this second group of 239 
experiments, the metabolic activity of the cells remained elevated in the EPS treated 240 
conditions (Fig 3B), regardless of the type of subsequent stimulation (p < 0.05-241 
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0.0001).  Treatment with LPS alone (red bars) also showed higher metabolic activity 242 
as measured by the MTS assay, and this was true regardless of whether or not they 243 
had been pre-treated with EPS (p < 0.0001). 244 
Apparent anomalies in the MTS results were observed for PHA treatment, where 245 
although a statistically significant activation was observed for two out of three donors 246 
tested (p < 0.05-0.01) the recorded levels did not correspond to the high level of cell 247 
proliferation observed on microscopic images for this condition (Fig 4).  It is possible 248 
that the conditions used for PHA stimulation interfered with the results of the MTS 249 
assay such that the level of metabolic activity that this assay measured did not 250 
accurately correspond to the level of proliferation exhibited after PHA stimulation [49, 251 
50] .  Microscopic inspection of the cells (Fig 4B) confirmed the high levels of 252 
proliferation and clumping of cells after PHA stimulation when compared to the 253 
unstimulated and untreated condition (Fig 4A) and the degree of cell aggregation was 254 
attenuated by previous treatment with EPS (Fig 4C).   255 
 256 
Fig. 4.  Representative microscopic images showing the effect of PHA with and 257 
without EPS pre-treatment on PBMC proliferation as seen at Day 2 of experiment 2.  258 
A. Untreated at Day 0, then washed and unstimulated at Day 1; B. Untreated at Day 0, 259 
then washed and stimulated with 10µg/ml PHA at Day 1; C. Pre-treated with 100µg/ml 260 
Lf2 HMw EPS at Day 0, then washed and stimulated with 10µg/ml PHA at Day 1.   261 
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 262 
The MTS assays gave results in agreement with previous reports, where the 263 
optimal PHA concentration for cell stimulation was 2.5 µg and where only modest 264 
increases in metabolic activity was reported for cultures stimulated with 10 µg/ml PHA 265 
[50]. From inspection of the microscope images it is clear that pre-treatment with the 266 
HMw-EPS partially reversed the effect of PHA by reducing the amount of cell 267 
aggregation and suggests that binding of the plant lectin or the resulting agglutination 268 
of the lectin bound cells is blocked. It is important to note that this reduced 269 
agglutination is taking place 24 h after the HMw-EPS has been removed which 270 
suggests that the initial exposure to the -glucan has changed the expression of lectin 271 
binding receptors on the surface of the PBMC. 272 
2.4 Flow cytometric assessment of pattern recognition receptors CD14 and TLR-2.  273 
In an attempt to measure changes in expression of surface receptors, in the next 274 
experiments, levels of expression of the pattern recognition receptors CD14 and TLR-275 
2 were studied.  After exposure of PBMC cells to the HMw-EPS for 24 h, in the three 276 
donors the average levels of expression CD14 were either marginally increased 277 
(Donor 1) or lower (Donor 2 and 3) compared to the untreated condition (p < 0.0001, 278 
Fig 5). Small decreases in CD14 levels in PBMC after 24 h stimulation with LPS has 279 
been previously reported [51].   Downregulation of CD14 expression after LPS 280 
stimulation was also observed in alveolar macrophages [52]. The results of the first 281 
experiments are in contrast to what was observed in the next set of experiments in 282 
which PBMC were treated with HMw-EPS for 24 h at which point the EPS was 283 
removed and then the cells were exposed to either no stimulant or to one of the 284 
stimulants LPS or PHA. Now prior-treatment with HMw-EPSled to a robust increase in 285 
the CD14 expression (Fig 5B). This was true for all conditions: untreated unstimulated 286 
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vs EPS pre-treated unstimulated (grey bars versus black bars); untreated LPS 287 
stimulated vs EPS pre-treated and LPS stimulated (red versus pink bars, with p < 288 
0.0001 in all cases), and in Donor B only, untreated PHA stimulated vs EPS pre-289 
treated and PHA stimulated (green versus olive bars p < 0.01).  290 
 291 
Fig 5.  Changes in CD14 expression on PBMC following different conditions presented 292 
as median fluorescence intensity (MFI) of CD14+ cells after A. Day 1 and B. Day 2 293 
experiment. A For Day 1, Unstimulated conditions were left untreated while Lf2 HMw 294 
50µg/ml and Lf2 HMw 100µg/ml were treated with EPS at indicated concentrations on 295 
Day 0 and incubated at 37˚C, 5% CO2.  Following 24h incubation, cells were 296 
harvested and stained with anti-CD14 antibody and analysed by flow cytometry. B For 297 
Day 2 experiment, Unstimulated condition was left untreated on Day 0, then washed 298 
and left unstimulated on Day 1.  Lf2 HMw 100µg/ml were pre-treated at Day 0 with 299 
indicated concentration of EPS, then washed and left unstimulated on Day 1.  LPS 300 
and PHA alone are conditions that were left untreated on Day 0, then washed and 301 
subsequently stimulated with 100ng/ml LPS and 10µg/ml PHA, respectively.  EPS + 302 
LPS and EPS + PHA represent the conditions that were pre-treated with EPS Lf2 303 
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HMw on Day 0, then washed and stimulated with 100ng/ml LPS and 10µg/ml PHA, 304 
respectively on Day 1.  Following 24h incubation, cells were harvested and stained 305 
with anti-CD14 antibody and analysed by flow cytometry.  Two-Way ANOVA was used 306 
to compare the conditions for each donor.  Data are presented as Mean ± SEM.  * p < 307 
0.05, *** p < 0.001, **** p < 0.0001 when compared to the untreated, unstimulated 308 
condition; # p < 0.05, ## p < 0.01, #### p < 0.0001 when compared between two 309 
indicated conditions.  Gates were set on single cells and debris was excluded using 310 
FSC vs SSC plots.  Gating was performed using FMO (Fluorescence Minus One) 311 
controls. 312 
 313 
The results suggest that the presence of -glucan does not immediately lead to a 314 
significant increase in production of CD14. Binding of the -glucan to CD14 may well 315 
result in internalisation of the receptor and the observation of reduced levels, as was 316 
seen in the first experiment for donors 2 and 3. In contrast, once the -glucan has 317 
been removed, and after a further incubation for 24 h, the cells now respond by 318 
significantly increasing the amount of the CD14 receptor present. As CD14 is a known 319 
receptor for bacterial antigens this might be expected to increase the signalling 320 
pathways leading to the release of proinflammatory mediators normally activated by 321 
antigens such as LPS but the reverse was observed (see discussion describing TNF- 322 
expression below).  323 
LPS stimulation, without EPS pretreatment (red bars, Fig 5B) led to a moderate 324 
decrease in CD 14 expression in two out of three donors (p < 0.0001 for Donor B and 325 
p < 0.01 for Donor C) whilst the levels of CD14 markers were marginally higher in 326 
Donor A (p < 0.0001). The latter results are identical to what was observed for the -327 
glucan in the first experiment and this suggests that the molecular mechanisms by 328 
which LPS and EPS stimulate PBMC may be the same. PHA is known to attenuate 329 
and down regulate expression of CD14 and this was observed in the second set of 330 
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experiments (p <0.0001 for all three donors). Pre-treatment with the -glucan only 331 
marginally reduced the decrease in expression caused by PHA, as seen in Donor B (p 332 
< 0.01).   333 
The effect of PBMC stimulation on TLR-2 expression was less consistent and the only 334 
result of note is that there was a clear decrease, in the second experiment, in TLR-2 335 
expression after -glucan pre-treatment, followed by LPS stimulation, compared to the 336 
LPS stimulated alone (p< 0.05 for Donor C and p < 0.0001 for Donors A and B, red 337 
versus pink bars Fig 6). For cells treated with PHA the data was also mixed with a 338 
stimulation of TLR-2 expression occurring in one donor and a reduction in one, in all 339 
cases pre-treatment with -glucan had no effect. 340 
 341 
Fig. 6.  Changes in TLR-2 expression on PBMC following different conditions 342 
presented as median fluorescence intensity (MFI) of TLR-2+ cells for the Day 2 343 
experiment. Unstimulated condition was left untreated on Day 0, then washed and left 344 
unstimulated on Day 1.  Lf2 HMw 100µg/ml were pre-treated at Day 0 with indicated 345 
concentration of EPS, then washed and left unstimulated on Day 1.  LPS and PHA 346 
alone are conditions that were left untreated on Day 0, then washed and subsequently 347 
stimulated with 100ng/ml LPS and 10µg/ml PHA, respectively.  EPS + LPS and EPS + 348 
PHA represent the conditions that were pre-treated with EPS Lf2 HMw on Day 0, then 349 
washed and stimulated with 100ng/ml LPS and 10µg/ml PHA, respectively on Day 1.  350 
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Following 24h incubation, cells were harvested and stained with anti-TLR-2 antibody 351 
and analysed by flow cytometry.  Two-Way ANOVA was used to compare the 352 
conditions for each donor.  Data are presented as Mean ± SEM.  * p < 0.05, ** p < 353 
0.01, *** p < 0.001, **** p < 0.0001 when compared to the untreated, unstimulated 354 
condition; # p < 0.05, #### p < 0.0001 when compared between two indicated 355 
conditions.  Gates were set on single cells and debris was excluded using FSC vs 356 
SSC plots.  Gating was performed using FMO (Fluorescence Minus One) controls.  357 
 358 
2.5 Stimulation of TNF-α secretion.  359 
Treatment of PBMC with HMw-EPS gave rise to a very large increase in TNF-α 360 
secretion, for both concentrations of the polysaccharide (Fig 7A).  TNF- is a 361 
proinflammatory mediator and is produced when LPS binds to CD14 activating the 362 
signalling pathway [19], the current results are consistent with a similar activation 363 
pathway being present for the HMw-EPS: binding of the glucan to CD14 leading to the 364 
release of TNF-. As was the case in the previous studies, in the next series of 365 
experiments PBMC cells were treated with HMw-EPS for 24 h, the -glucan was 366 
removed before adding either no stimulant or one of the stimulants LPS or PHA and 367 
incubating the cells for a further 24 h. When the PBMC cells were left unstimulated in 368 
the second part of these experiments the levels of TNF- returned to values similar to 369 
the controls. On first inspection, this result is not surprising: the -glucan is no longer 370 
present to bind to CD-14 and, as such, the signalling pathway should no longer be 371 
activated. However, results with LPS suggest an alternative explanation involving 372 
desensitization of the signalling pathway could also explain this result. 373 
When LPS was added as a stimulant to cells that had been exposed to the HMW-374 
EPS, a very significant reduction in TNF- production was observed compared to the 375 
control in which the PBMC cells had not been exposed to the HMw-EPS where a large 376 
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increase in TNF- production was observed (Fig 7B red versus very small pink bars). 377 
The failure to observe TNF- secretion in cells which had been treated with HMw-EPS 378 
and then exposed to LPS could be thought of as unexpected. However, this type of 379 
desensitization is observed in other signalling pathways, a number of activation 380 
cascades include steps in which there is a transformation of a binding component e.g. 381 
by phosphorylation, which desensitizes a cell surface receptor such that the signal can 382 
be rapidly stopped [53]. This would have an advantage during the release of 383 
proinflammatory mediators where it would prevent an excessive inflammatory 384 
response. Before the signal can be reinstated, the receptor needs to be recycled so it 385 
can be reactivated. Incubation of PBMC cells with PHA produced a robust stimulation 386 
of TNF- confirming that the cells used here were immune competent and although 387 
less dramatic than after LPS stimulation pre-treatment with the -glucan also reduced 388 
the amount of TNF- secreted. 389 
The key findings on the role of the HMw-EPS on the immune stimulation of PBMC are 390 
that when the cells were pretreated with the -glucan and subsequently stimulated 391 
with the bacterial antigen LPS the secretion of TNF- was virtually abolished. This 392 
effect is at least in part mediated by a reduction in the TLR-2, which is a target for 393 
LPS. When the PMBC that had been pretreated with the -glucan were stimulated with 394 
PHA there was also a reduction in the secretion of TNF- but this was much less 395 
marked. These data suggest that this -glucan which of bacterial origin has a greater 396 
role in reducing the inflammation produced by LPS which is produced by enteric 397 
bacteria. However, the PHA data indicate that the -glucan can play a more general 398 
role in the reduction of inflammation. 399 
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 400 
Fig. 7.  Changes in TNF-α levels in cell culture supernatants following different 401 
conditions after A. Day 1 and B. Day 2 experiment. A For Day 1, Unstimulated 402 
conditions were left untreated while Lf2 HMw 50µg/ml and Lf2 HMw 100µg/ml were 403 
treated with EPS at indicated concentrations on Day 0 and incubated at 37˚C, 5% 404 
CO2.  Following 24h incubation, supernatants were stored at -80˚C until subsequent 405 
analysis for TNF-α levels by ELISA.  B For Day 2 experiment, Unstimulated condition 406 
was left untreated on Day 0, then washed and left unstimulated on Day 1.  Lf2 HMw 407 
100µg/ml were pre-treated at Day 0 with indicated concentration of EPS, then washed 408 
and left unstimulated on Day 1.  LPS and PHA alone are conditions that were left 409 
untreated on Day 0, then washed and subsequently stimulated with 100ng/ml LPS and 410 
10µg/ml PHA, respectively.  EPS + LPS and EPS + PHA represent the conditions that 411 
were pre-treated with EPS Lf2 HMw on Day 0, then washed and stimulated with 412 
100ng/ml LPS and 10µg/ml PHA, respectively on Day 1.  Following 24h incubation, 413 
supernatants were stored at -80˚C until subsequent analysis for TNF-α levels by 414 
ELISA. Two-Way ANOVA was used to compare the conditions for each donor.  Data 415 
are presented as Mean ± SEM.  ** p < 0.01, **** p < 0.0001 when compared to the 416 
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untreated, unstimulated condition; # p < 0.05, ## p < 0.01, #### p < 0.0001 when 417 
compared between two indicated conditions 418 
 419 
TNF-α is a key proinflammatory cytokine, the blocking of its release by the HMw-EPS 420 
could produce an immune tolerant phenotype, with potentially important implications 421 
given TNF- has a central role in the aetiology of inflammatory bowel diseases such 422 
as Crohn’s disease and ulcerative colitis. Further work is needed to determine the 423 
mechanism by which the HMW-EPS blocks TNF-production.  424 
3. Experimental Section 425 
3.1 Materials  426 
Unless otherwise stated, reagents were purchased from Sigma-Aldrich Company 427 
Ltd. (Poole, Dorset UK) and were used as supplied. 428 
3.2 EPS production and purification.  429 
L. fermentum Lf2 was grown at the Instituto de Lactologia Industrial (Santa Fe, 430 
Argentina). The growth conditions, as well as the crude EPS extraction and purification 431 
methods have been reported [31, 54]. Size Exclusion Chromatography coupled with 432 
Multi-Angle Laser Light Scattering (SEC-MALLS-Wyatt technology, Santa Barbara, CA, 433 
USA) was used to determine the composition of the crude EPS. EPS samples (1 mg/mL) 434 
were prepared in aq. NaNO3 (0.1M) and stirred for 16 h to ensure the EPS was 435 
completely dissolved. Samples (100 µL) were injected, in triplicate, into a SEC-MALLS 436 
system (three columns connected in series: PL Aquagel-OH 40, 50 and 60 (8 μm, 30 437 
cm x 7.5 mm, Agilent, Cheadle, UK) with a flow rate of 0.7 mL/min. A differential 438 
refractometer (Optilab rEX, Wyatt technology, Santa Barbara, CA, USA) was used to 439 
determine the concentration of the polysaccharide and a Dawn-EOS MALLS detector 440 
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(laser operating at 690 nm) was used to determine the weight average molecular mass 441 
of the polysaccharide. An in-line UV detector (Shimadzu, Milton Keynes, UK) was used 442 
for the detection of proteins and nucleic acids. ASTRA version 6.0.1 software (Wyatt 443 
technology, Santa Barbara, CA, USA) was used for the data analysis.  444 
The crude EPS was purified by preparative size exclusion chromatography on a 445 
Sephacryl S-500 HR column (XK26/60-GE Healthcare, Fisher Scientific, UK) eluting 446 
with ultrapure water at a flow rate of 5.0 mL min-1 using a FPLC kit (AKTA PRIME-447 
Amersham Pharmacia, Biotech, GE Healthcare Life Sciences, Buckinghamshire, UK) 448 
with a set wavelength of 254 nm. In total, sixty 5 mL fractions were collected and the 449 
location of polysaccharides in the different fractions was identified by determining the 450 
carbohydrate content of each fraction using the Dubois method [55, 56]. Fractions 451 
containing EPS were pooled and freeze-dried. 452 
3.3 NMR analysis of the high molecular mass EPS.  453 
NMR spectra of the EPS were recorded in solution in D2O (5-10 mg in 0.65 mL) 454 
and were run at 70 °C on Bruker NMR spectrometers at either 400, 500 or 600 MHz 455 
(Bruker-biospin, Coventry, UK) using Bruker’s TOPSPIN 4.0.1 software for analysis. 456 
Chemical shifts are expressed in ppm relative to internal acetone, 2.225 for 1H and 457 
31.55 for 13C. A series of 2D-spectra were recorded including: a 2D gradient-selected 458 
double quantum filtered correlation spectrum (gs-DQF-COSY) recorded in magnitude 459 
mode; a total correlation spectroscopy (TOCSY) experiment recorded with a mixing 460 
times of 120 ms;  1H-13C heteronuclear single quantum coherence (HSQC) spectra 461 
(decoupled and coupled); and finally, a rotating frame nuclear Overhauser effect 462 
spectrum (ROESY, mixing time of 200 ms). The 2D spectra were recorded with 256 463 
experiments of 1024 data points. For the majority of spectra, time-domain data were 464 
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multiplied by phase-shifted (squared-) sine-bell functions. After applying zero filling 465 
and Fourier transformation, data sets of 1024-1024 points were obtained. 466 
3.4 Composition of the high molecular weight polysaccharide.  467 
The monosaccharides present were determined after acid hydrolysis either 468 
directly using HPAEC-PAD analysis or as their alditol acetates, as previously 469 
described [24]. The absolute configuration of the sugars was determined by 470 
preparation of their respective 2-(S)-butylglycosides using Gerwig’s method [57]. For 471 
linkage analysis, the samples were permethylated using the procedures described by 472 
Stellner [58].  473 
3.5 PBMC isolation and cell culture.  474 
Venous blood was collected after obtaining informed consent from three healthy 475 
volunteers in blood collecting tubes containing citrate-dextrose solution (ACD) at a 476 
whole blood to anticoagulant ratio of 9:1. The study was approved by the Local Ethics 477 
Committee (School of Applied Sciences, University of Huddersfield, UK).  Blood 478 
samples were layered over Histopaque®-1077 and PBMC isolated using a standard 479 
density gradient centrifugation protocol. Enriched PBMC were suspended in RPMI 480 
1640 medium (Gibco, Life Technologies, UK) supplemented with 4 mM L-glutamine, 481 
50 IU/ml/50 μg/ml/ penicillin/streptomycin and 20 mM HEPES (all from Gibco, Life 482 
Technologies, UK) and 10% heat-inactivated fetal bovine serum (FBS) and 2x106 483 
cells/well were added to 24-well plates (Starlab, UK).  The cells were then challenged 484 
as shown in Figure 8.  For the Day 1 experiment (Fig 8A), cells were treated with two 485 
different concentrations of EPS (50 µg/mL and 100µg/mL) or left untreated, four 486 
replicates were set up for each condition.  For the Day 2 experiment (Fig 8B), at Day 487 
0, half of the wells were treated with 100 µg/mL EPS while the other half was left 488 
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untreated. Cells were incubated for 24 h, at 37 ˚C, 5% CO2 after which they were 489 
washed with supplemented RPMI 1640 and stimulated with either LPS 490 
(Lipopolysaccharides from Escherichia coli O111:B4) at a final concentration of 100 491 
ng/mL or PHA-M (Lectin from Phaseolus vulgaris (red kidney bean)) at 10 µg/ml, or 492 
left unstimulated (Fig 8B) (final incubation of 24 h, at 37 oC, 5% CO2). Each condition 493 
was set up in four replicates.  494 
 495 
Fig. 8. Schematic representation of the cell culture protocol completed on A. 496 
Experiment 1 and B. Experiment 2.  A. On Day 0, cells were treated with two different 497 
Lf2 HMw EPS concentrations (50µg/ml and 100µg/ml) or left untreated at 37˚C, 5% 498 
CO2.  Following 24h incubation, supernatants were taken off and stored at -80˚C for 499 
subsequent analysis by ELISA.  Cells were harvested and 1x105 cells/well were 500 
transferred into 96-well plates for MTS assay performed following the supplier’s 501 
instructions.  The remaining cells were stained with antibodies for CD14 and TLR-2 502 
and analysed for the expression of these markers by flow cytometry.  B. on Day 0 cells 503 
were pre-treated with 100µg/ml EPS or left untreated and incubated for 24h at 37˚C, 504 
5% CO2.  On Day 1, cells were washed to remove EPS and were stimulated with LPS 505 
(100ng/ml) or PHA (10µg/ml) or left unstimulated and incubated for another 24h at 506 
37˚C, 5% CO2.  On Day 2, supernatants were then stored at -80˚C for subsequent 507 
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cytokine analysis by ELISA.  As before 1x105 of harvested cells/well were transferred 508 
into 96-well plate for MTS assay while remaining cells were stained for flow cytometric 509 
analysis of CD14 and TLR-2 expression.   510 
 511 
3.6 MTS assay.  512 
In order to measure the metabolic activity of the cell cultures under different 513 
conditions, the CellTiter 96® AQueous One Solution Cell Proliferation Assay, MTS 514 
assay (Promega, UK) was used as per the manufacturer’s instructions.  At the end of 515 
each experiment 1x105 cells from individual wells were transferred into separate wells 516 
of a 96-well plate and tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-517 
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS) and an 518 
electron coupling reagent (phenazine ethosulfate; PES) were added and the 519 
absorbance at 490nm was measured.   520 
3.7 Flow cytometry.  521 
To monitor CD14 and TLR-2 expression the remaining PBMC were washed with 522 
FACS buffer (PBS, Lonza, UK, 1% Bovine serum albumin, BSA, 0.1% sodium azide, 523 
Sigma Aldrich, UK), and fixed with 1% paraformaldehyde (PFA, Sigma Aldrich, UK).  524 
Cells were then washed with permeabilisation solution (Perm Wash, BD Biosciences, 525 
UK) and stained with anti-CD14 and anti-TLR-2 antibodies (Biolegend, UK).  Following 526 
the incubation, cells were washed with Perm Wash buffer and resuspended in 1% 527 
PFA until acquisition using The Guava® easyCyte flow cytometer (Merck Milipore, 528 
UK).  Data were acquired using guavaSoft 2.7 software for Windows and analysed 529 
using its 3.1.1. version. Data were presented as median fluorescence intensity 530 
indicating the level of marker’s expression (MFI of CD14+ and MFI of TLR-2+ cells).  531 
Doublet and debris exclusion were performed and gating was set based on 532 
Fluorescence Minus One (FMO) controls. 533 
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3.8 Measurement of TNF-α levels by ELISA.  534 
Stored supernatants were used for the analysis of TNF-α concentration by ELISA 535 
(TNF alpha (Total) Human ELISA Kit, Invitrogen, UK) following the manufacturer’s 536 
instructions.  Briefly, the plate was coated with TNF-α specific capture antigen and left 537 
overnight.  Following subsequent washes, non-specific binding was blocked using 538 
blocking buffer after which samples were added and incubated for 2 h at room 539 
temperature.  Plates were then washed and biotinylated detection antibody was 540 
added, after which avidin horseradish peroxidase (avidin-HRP) was used to bind to the 541 
biotin on the detection antibody.  Tetramethylbenzidine was then added as the 542 
substrate for the HRP enzyme, and the reaction was stopped with the addition of 1M 543 
sulfuric acid.  Absorbance was read at 495nm using FLUOstar Optima plate reader 544 
(BMG Labtech). The data were analysed using MARS Data Analysis Software, and a 545 
4-parameter logistic regression curve was used as the best fit for the data.   546 
3.9 Statistical analyses.  547 
Due to the variability between the donors, each was treated as a separate group 548 
and Two-Way analysis of variance (ANOVA) followed by Tukey’s posthoc test for 549 
multiple comparison were used to examine the differences between the conditions.  550 
For each donor, data are presented as mean ± SEM (standard error of the mean) of 551 
the replicates of the conditions set up in experiment. 552 
  553 
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